Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Trial to Assess the Efficacy and Safety of Adding GMA to Infliximab in Paediatric Patients With Steroid-refractory Ulcerative Colitis

NCT05430412 is registered in ClinicalTrials.gov with Adacyte Therapeutics SL as lead sponsor.

NCT NCT05430412
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05430412 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Trial to Assess the Efficacy and Safety of Adding GMA to Infliximab in Paediatric Patients With Steroid-refractory Ulcerative Colitis
Lead sponsor
Adacyte Therapeutics SL
Phase
Not applicable
Overall status
Unknown status
Start date
January 11, 2022
Completion date
October 31, 2024
Enrollment
15 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis